4DMT Surges on Positive 60-Week Clinical Trial Data

4D Molecular Therapeutics shares are trading higher after announcing positive results from their SPECTRA clinical trial for 4D-150 in diabetic macular edema, along with alignment on a registrational pathway with the European Medicines Agency.